Differences about effectiveness of CGM and treatment satisfaction between dulaglutide and omarigliptin.
Not Applicable
Recruiting
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000021953
- Lead Sponsor
- TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who has renal dysfunction (eGFR is less than 30ml/min/1.73m2) 2. Pregnant women 3. Patients judged by the doctor to be ineligible
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which dulaglutide and omarigliptin regulate glucose metabolism in type 2 diabetes mellitus?
How does the efficacy of continuous glucose monitoring (CGM) with dulaglutide compare to standard-of-care treatments in type 2 diabetes mellitus patients?
What biomarkers are associated with treatment satisfaction and response prediction in type 2 diabetes mellitus patients using dulaglutide or omarigliptin?
What are the known or potential adverse events associated with dulaglutide and omarigliptin in type 2 diabetes mellitus management?
How do dulaglutide and omarigliptin compare to other GLP-1 receptor agonists and DPP-4 inhibitors in terms of CGM effectiveness and treatment satisfaction for type 2 diabetes mellitus?